Targeted first-line therapies for advanced colorectal cancer: a Bayesian meta-analysis

Area of Science:

• Oncology
• Medical Research
• Clinical Trials

Background:

• Colorectal cancer (CRC) is a leading cause of cancer death.
• First-line treatments for metastatic CRC include FOLFIRI and FOLFOX.
• Combination therapies with anti-EGFR or anti-VEGF antibodies are used, but optimal strategies are unclear.

Purpose of the Study:

• To evaluate the efficacy of first-line FOLFIRI or FOLFOX combined with anti-EGFR or anti-VEGF antibodies in advanced colorectal cancer.
• To analyze treatment effectiveness across different patient subgroups, particularly based on RAS mutation status.

Main Methods:

• Systematic literature search for randomized trials comparing chemotherapy (FOLFIRI/FOLFOX) plus anti-EGFR or anti-VEGF versus chemotherapy alone.
• Meta-analysis using a Bayesian hierarchical log-linear model.
• Primary endpoint: overall survival.

Main Results:

• No significant impact of FOLFIRI/FOLFOX on the efficacy of anti-EGFR or anti-VEGF antibodies across mutation groups was found.
• Both anti-EGFR and anti-VEGF therapies appear more effective in KRAS wild-type (WT) than KRAS mutated (MT) patients.
• Anti-EGFR may be superior to anti-VEGF in KRAS WT patients when combined with FOLFIRI/FOLFOX. In KRAS MT patients, these combinations might be harmful compared to chemotherapy alone.

Conclusions:

• Further research is needed on the impact of all-RAS mutation status on treatment efficacy.
• Tumor location (left vs. right side) requires further investigation.
• The combination of anti-VEGF with modern fluoropyrimidine regimens warrants additional study.